KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.90

Therapeutic serum level for adalimumab in rheumatoid arthritis: explorative analyses of data from a randomised phase III trial.

Johanna Elin Gehin, Rolf Anton Klaasen, Eirik Klami Kristianslund, Ingrid Jyssum, Joseph Sexton, David John Warren, Daniel Aletaha, Espen Andre Haavardsholm, Silje Watterdal Syversen, Guro Løvik Goll, Nils Bolstad

RMD Open 10(4) e004888

PMID39537558
PMCIDPMC11575345
DOI10.1136/rmdopen-2024-004888
发表日期2024-11-13
入排依据:The study is a randomized phase III trial with a drug intervention (adalimumab) and reports original results, but it is not an oncology study (rheumatoid arthritis) and does not have a time-to-event efficacy endpoint. The primary outcomes are categorical (remission/low disease activity) and continuous (CRP levels), not survival or progression metrics.
摘要

摘要

OBJECTIVES: The objectives of this study are to identify a therapeutic serum level for adalimumab associated with remission and low disease activity in patients with rheumatoid arthritis. METHODS: Associations between serum adalimumab trough levels and disease activity were examined using longitudinal data from a 48-week randomised phase III trial including patients with tumour necrosis factor inhibitor-naïve rheumatoid arthritis with active disease starting adalimumab treatment. Disease activity was classified according to 28-joint Disease Activity Score (DAS28)-erythrocyte sedimentation rate and C reactive protein (CRP) levels. RESULTS: Adalimumab trough levels were recorded longitudinally for 336, 330 and 302 patients at weeks 12, 24 and 48, respectively. All patients received concomitant methotrexate. Median adalimumab trough levels were 6.4 mg/L (IQR 3.4-9.5) at week 12, 7.5 mg/L (IQR 3.5-10.9) at week 24 and 7.6 mg/L (IQR 3.6-12.0) at week 48. In serial serum samples from weeks 12, 24 and 48, trough levels ≥3.9 mg/L were associated with DAS28 remission (OR 3.88 (95% CI 1.80, 8.38), p<0.001) and lower CRP levels (p<0.001). Week 12 trough levels ≥3.5 mg/L were associated with DAS28 low disease activity at week 24 (OR 2.62 (1.50, 4.56), p<0.001) and remission at week 48 (OR 1.99 (1.02, 3.88), p=0.04), as well as lower CRP levels at both time points (p<0.001). CONCLUSION: Adalimumab trough levels above 4.0 mg/L were associated with remission/low disease activity throughout the first year of adalimumab therapy and can be considered a lower target level for therapeutic drug monitoring of adalimumab therapy.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。